Kolon TissueGene, Inc. (KOSDAQ:950160)

Market Cap	3.65T
Revenue (ttm)	5.49B
Net Income (ttm)	-87.80B
Shares Out	83.22M
EPS (ttm)	-1,097.18
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	264,454
Average Volume	252,743
Open	44,200
Previous Close	44,100
Day's Range	43,000 - 44,600
52-Week Range	14,600 - 59,300
Beta	-0.66
RSI	46.86
Earnings Date	n/a

About Kolon TissueGene

Kolon TissueGene, Inc. develops cell therapies for orthopedic diseases and other unmet medical needs. The company’s lead product is the TG-C that has completed Phase II trials to treat osteoarthritis, as well as rheumatoid arthritis, meniscus, and spinal discs. It is also developing cell therapies for musculoskeletal system disorders, as well as vet medicine. Kolon TissueGene, Inc. was formerly known as TissueGene, Inc. and changed its name to Kolon TissueGene, Inc. in March 2018. The company was founded in 1999 and is headquartered in Rockvill...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 29
• Stock Exchange: KOSDAQ
• Ticker Symbol: 950160

Financial Performance

In 2024, Kolon TissueGene's revenue was 5.07 billion, an increase of 36.90% compared to the previous year's 3.71 billion. Losses were -33.80 billion, 96.2% more than in 2023.